Workflow
Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance (NYSE:HAE)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...